The clinical relevance of the p53 tumour suppressor gene*
1994; Wiley; Volume: 5; Issue: 3 Linguagem: Inglês
10.1111/j.1365-2303.1994.tb00409.x
ISSN1365-2303
Autores Tópico(s)Pancreatic and Hepatic Oncology Research
ResumoCytopathologyVolume 5, Issue 3 p. 133-145 The clinical relevance of the p53 tumour suppressor gene* S. P. DOWELL, S. P. DOWELL Department of Pathology, Ninewells Hospital and Medical School, University of Dundee, Dundee, UKSearch for more papers by this authorP. A. HALL, Corresponding Author P. A. HALL Department of Pathology, Ninewells Hospital and Medical School, University of Dundee, Dundee, UKProfessor P. A. Hall, Department of Pathology, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK.Search for more papers by this author S. P. DOWELL, S. P. DOWELL Department of Pathology, Ninewells Hospital and Medical School, University of Dundee, Dundee, UKSearch for more papers by this authorP. A. HALL, Corresponding Author P. A. HALL Department of Pathology, Ninewells Hospital and Medical School, University of Dundee, Dundee, UKProfessor P. A. Hall, Department of Pathology, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK.Search for more papers by this author First published: June 1994 https://doi.org/10.1111/j.1365-2303.1994.tb00409.xCitations: 20 * Based in part on a lecture given by P.A.H. at the BSCC Annual Scientific Meeting, Bristol, UK, September 1992. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Bishop JM. Molecular themes in oncogenesis. Cell 1991; 64: 235–48. 2 Hunter T. Cooperation between oncogenes. Cell 1991; 64: 249–70. 3 Marshall CJ. Tumour suppressor genes. Cell 1991; 64: 313–26. 4 Weinberg RA. Tumour suppressor genes. Science 1991; 254: 1138–46. 5 Lane DP. p53, guardian of the genome. Nature 1992; 358: 15–16. 6 Lane DP, Crawford LV. T-antigen is bound to a host protein in SV40 transformed cells. Nature 1979; 278: 261–3. 7 Linzer DIH, Levine AJ. Characterization of a 54 k dalton cellular SV40 tumour antigen present in SV40 transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17: 43–52. 8 Parada LF, Land H, Weinberg RA, Wolf D, Rotter V. Co-operation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 1984; 312: 649–51. 9 Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsp70-p53 complex with an altered half life. Mol Cell Biol 1988; 8: 531–9. 10 Finlay CA, Hinds PW, Levine AJ. the protooncogene p53 can act as a suppressor of transformation. Cell 1989; 57: 1083–93. 11 Lane DP, Benchimol S. Oncogene or antioncogene Genes Dev 1990; 4: 1–8. 12 Hinds P, Finlay C, Levine AJ. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 1989; 63: 739–46. 13 Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. Wild type p53 can inhibit oncogene mediated focus formation. Proc Natl Acad Sci USA 1989; 86: 8763–7. 14 Casey G, Lo-Hsueh M, Lopez ME, Vogelstein B, Stanbridge EJ. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 1991; 6: 1791–7. 15 Levine AJ, Momand J, Finlay CA. the p53 tumour suppressor gene. Nature 1991; 351: 453–6. 16 Bartek J, Bartkova J, Vojtesek B et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991; 6: 1699–703. 17 Nigro JM, Baker SJ, Preisinger AC et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705–8. 18 Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49–53. 19 Werness BA, Levine AJ, Howley PM. Association of human papilloma virus types 16 and 18 E6 proteins with p53. Science 199; 248: 76–79. 20 Mietz JA, Unger T, Huibregtse JM, Howley PM. the transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 1992; 11: 5013–20. 21 Jenkins JR, Rudge K, Currie GA. Cellular immortalisation by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature 1984; 312: 651–4. 22 Kastan MB, Onyekwere O, Sidransky D et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304–11. 23 Kuerbitz SJ, Plunkett BS, Walsh WV et al. Wild type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992; 89: 7491–5. 24 Lin D, Shields MT, Ullrich SJ, Appella E, Mercer WE. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc. Natl Acad Sci USA 1992; 89: 9210–4. 25 Kern SE, Kinzer KW, Bruskein A et al. Identification of p53 as a sequence specific DNA-binding protein. Science 1991; 252: 1708–11. 26 Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C. Wild-type p53 activates transcription in vitro. Nature 1992; 358: 83–86. 27 Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell 1992; 71: 875–84. 28 Malkin D, Li FP, Strong LC et al. Germ line p53 mutations in a familial syndrome of breast cancer. sarcomas and other neoplasms. Science 1990; 250: 1233–8. 29 Barnes DM, Hanby AM, Gillett CE et al. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 1992; 340: 259–63. 30 Kraiss S, Quaiser A, Oren M, Montenarh JH. Oligomerization of oncoprotein p53. J Virol 1988; 62: 4737–44. 31 Milner J, Metcalf EA, Cook AC. Tumour suppressor p53: analysis of wild type and mutant p53 complexes. Mol Cell Biol 1991; 11: 12–19. 32 Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990; 9: 1595–602. 33 Iggo R, Gatter K, Bartek J, Lane DP, Harris A. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675–9. 34 Cunningham J, Lust JA, Schaid DJ et al. Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res 1991; 52: 1974–80. 35 Shaw P, Tardy S, Benito E, Obrador A, Costa J. Occurrence of Ki-ras and p53 mutations in primary colorectal tumors. Oncogene 1991; 6: 2121–8. 36 Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992; 71: 543–6. 37 Livingstone LR, Whiute A, Sprouse J et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992; 70: 923–35. 38 Yin Y, Tainskey MA, Bischoff FZ et al. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70: 937–48. 39 Hall PA, McKee PHDUP, Menage H, Dover R, Lane DP. High levels of p53 protein in UV irradiated normal human skin. Oncogene 1993; 8: 203–7. 40 Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumour antigen in non-transformed mouse cells. Mol Cell Biol 1984; 4: 1689–94. 41 Lane DP. A death in the life of p53. Nature 1993; 362: 786–7. 42 Shaw P, Bovey R, Tardy S et al. Induction of apoptosis by wild-type p53 in human colon tumour-derived cell line. Proc Natl Acad Sci USA 1992; 89: 4495–9. 43 Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid cells that is inhibited by interluekin-6. Nature 1991; 352: 345–7. 44 Donehower LA, Harvey M, Slagle BL et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215–21. 45 Holliday R. Chromosome error propagation and cancer. Trends Genet 1989; 5: 42–45. 46 Matsumura K, Kallioniemi A, Kallioniemi O et al. Deletion of chromosome 17p loci in breast cancer cells detected by fluorescence in situ hybridization. Cancer Res 1992; 52: 3474–7. 47 Soussi T, de Fromental CC, May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogens 1990; 5: 945–52. 48 Barton CM, Staddon SL, Hughes CM et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991; 64: 1076–82. 49 Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989; 86: 2766–70. 50 Sakai E, Rikimaaru K, Ueda M et al. the p53 tumor-suppressor gene and ras oncogene mutations in oral and squamous-cell carcinoma. Int J Cancer 1992; 52: 867–72. 51 Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi JH. Mutation pattern of the p53 gene as a diagnostic marker for multiple hepato-cellular carcinoma. Cancer Res 1992; 52: 3674–8. 52 Mohabeer AJ, Hiti AL, Martin WJ. Nonradioactive single strand conformation polymorphism (SSCP) using the Pharmacia ‘PhastSystem. Nucl Acids Res 1991; 19: 3154. 53 Serra A, Gaidano GL, Revello D et al. A new Taql polymorphism in the p53 gene. Nucl Acids Res 1992; 20: 928. 54 Bhatia K, Gutierrez MI, Huppi K, Magrath IT. PCR detection of a neutral CGA/CGG dimorphism in exon 6 of the human p53 gene. Nucl Acids Res 1992; 20: 928. 55 Dowell SP, Lane DP, Hall PA. the immunocytochemical detection of p53 protein in cytological specimens: technical considerations. Cytopathology June 1994; 5: 76–81. 56 Wynford-Thomas D. p53 in tumour pathology: can we trust immunohistochemistry J Pathol 1992; 166: 329–30. 57 Vojtesek B, Lane DP. Regulation of p53 protein expression in human breast cancer cell lines. J Cell Sci 1993; 105: 607–12. 58 McKee PH, Hobbs C, Hall PA. Antigen retrieval by microwave irradiation lowers immunohistological detection thresholds. Histopathology 1993; 23: 377–9. 59 Lambkin HA, Mothersill CM, Kelehan P. Variations in immunohistochemical detection of p53 protein overexpression in cervical tumours with different antibodies and methods of detection. J Pathol June 1994; 172: 13–20. 60 Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry… revisited. J Pathol June 1994; 172: 1–4. 61 Maestro R, Dolcetti R, Gasparotto D et al. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene 1992; 7: 1159–66. 62 Kohler MF, Berchuck A, Davidoff AM et al. Overexpression and mutation of p53m in endometrial carcinoma. Cancer Res 1992; 52: 1622–27. 63 Davidoff AM, Humphrey PA, Iglehart JD, Marks JR. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 1991; 88: 5006–10. 64 Dei-Tos AP, Doglioni C, Laurino L, Barbareschi M, Fletcher CDM. p53 protein expression in nonneoplastic lesions and benign and malignant neoplasms of soft tissue. Histopathology 1993; 22: 45–50. 65 Pignatelli M, Stamp GW, Kafiri G, Lane D, Bodmer WF. Over-expression of p53 nuclear oncoprotein in colorectal adenomas. Int J Cancer 1991; 50: 683–8. 66 Soini Y, Vahakangas K, Nuorva K, Kamel D, Lane DP, Paakko P. p53 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumours. J Pathol 1992; 168: 29–33. 67 Sim CS, Slater S, McKee PH. Mutant p53 expression in solar keratosis: an immunohistochemical study. J Cutan Pathol 1992; 19: 302–8. 68 Taguchi M, Watanbe S, Sato Y et al. Immunohistochemical examination of tumor-suppressor gene p53 product and pyrimidine dimer in solar keratosis. J Cancer Res Clin Oncol 1993; 119: 260–2. 69 Gusterson BA, Anbazhagan R, Warren W et al. Expression of p53 in premalignant and malignant squamous epithelium. Oncogene 1991; 6: 1785–9. 70 Sim CS, Slater SD, McKee PH. Mutant p53 protein is expressed in Bowen's disease. Am J Dermatopathol 1992; 14: 195–9. 71 Baas IO, Mulder J-WR, Offerhaus JA, Vogelstein B, Hamilton SR. an evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol June 1994; 172: 5–12. 72 Scarpa A, Capelli P, Mukai K et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993; 142: 1534–43. 73 Hall PA, Ray A, Lemoine NR, Midgley CA, Krausz T, Lane DP. p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet 1991; 338: 513. 74 Dowell SP, Wilson POG, Derias NW, Lane DP, Hall PA. The clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Submitted. 75 Sakai E, Tsuchida N. Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumour-suppressor genes. Oncogene 1992; 7: 927–33. 76 Ogden GR, Kiddie RA, Lunny DP, Lane DP. Assessment of p53 protein expression in normal, benign, and malignant oral mucosa. J Pathol 1992; 166: 389–94. 77 Ramael M, Lemmens G, Erdekens C et al. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol 1992; 168: 371–5. 78 Mayall FG, Goddard H, Gibbs AR. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. J Pathol 1992; 168: 377–81. 79 Kafiri G, Thomas DM, Shepherd NA, Krausz T, Lane DP, Hall PA. p53 expression is common in malignant mesothelioma. Histopathology 1992; 21: 331–4. 80 Dowell S, Derias N, Wilson POG, Lane DP, Hall PA. Expression of p53 in reactive mesothelium. Histopathology 1993; 22: 96–97. 81 Perkins P, Jin L, Naylor B, Lloyd R. Comparison of p53 immunohistochemical staining of epithelial mesotheliomas and reactive mesothelial proliferations (abstract). Lab Invest 1993; 68: 341A. 82 Thorlacius S, Borresen A-L, Eyfyord JE. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res 1993; 53: 1637–41. 83 Sawan A, Randall B, Angus B et al. Retino-blastoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study. J Pathol 1992; 68: 23–28. 84 Iwaya K, Tsuda H, Hiraide H et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 1991; 82: 835–40. 85 Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RA. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis Human Pathol 1993; 24: 469–76. 86 Isola J, Visakorpi T, Holli K, Kallioniemi O-P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992; 84: 1109–14. 87 Allred DC, Clark GM, Elledge R et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200–6. 88 Thor AD, Moore II DH, Edgerton SM et al. Accumulation of p53 tumour suppressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst 1992; 84: 847–54. 89 Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992; 50: 859–62. 90 Starzynska T, Bromley M, Gosh A, Stern PL. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992; 66: 558–62. 91 Bell SM, Scott N, Cross D et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993; 104: 57–64. 92 Yamaguchi A, Kurosaka Y, Fushida S et al. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 1992; 70: 2778–84. 93 Sun X, Carstensen JM, Zhang H et al. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 1992; 340: 1369–72. 94 Remvikos Y, Tominaga O, Hammel P et al. Increase p53 protein content of colorectal tumours correlated with poor survival. Br J Cancer 1992; 66: 758–64. 95 Sarkis AS, Dalbagni G, Cordon-Cardo C et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993; 85: 53–59. 96 Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 1993; 53: 365–70. 97 Jaros E, Perry RH, Adam L et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 1992; 66: 373–85. 98 Gitsch G, Kainz C, Joura E, Breitenecker G. Mutant p53 product in patients with Stage III cervical cancer. Anticancer Res 1992; 12: 2241–2. 99 Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992; 52: 4828–31. 100 Horio Y, Takahashi T, Kuroishi T et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993; 53: 1–4. 101 Volm M, Efferth T, Mattern J. Oncoprotein (c-myc, c-erbB2, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res 1992; 12: 11–20. 102 Visakorpi T, Kallioniemi O-P, Keikkinen A, Koivula T, Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992; 84: 883–7. 103 Stephenson TJ, Royds JA, Silcocks PB, Brammer HJ, Shorthouse AJ, Underwood JCE. Diagnostic association of p53 immunostaining in fine needle aspiration cytology of the breast. Cytopathology June 1994; 5: 146–53. 104 Koutselini H, Malliri A, Field JK, Spandidos DA. p53 expression in cytological specimens from benign and malignant breast lesions. Anticancer Res 1991; 11: 1415–20. Citing Literature Volume5, Issue3June 1994Pages 133-145 ReferencesRelatedInformation
Referência(s)